KRAS and neoplasm: Hence, targeting cells with KRAS mutations by small interfering RNA (siRNA), short hairpin RNA (shRNA), or KRAS mutation-specific small molecule inhibitors can be considered as tumor cell-specific targeting strategy with less off-target side effects.